Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data M.

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

Laboratory diagnosis and biosafety issues of biological warfare agents

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Pharmacokinetics of cefetamet pivoxil and interaction with cisapride and N- acetylcysteine Klaus-Jürgen Gutleben, Jörg Eller, Jessica Vöckler, Margot.

Pharmacokinetics in vivo and pharmacodynamics ex vivo/in vitro of meropenem and cefpirome in the Yucatan micropig model: continuous infusion versus intermittent.

Circulating levels of sTNFR and discrepancy between cytotoxicity and immunoreactivity of TNF-α in patients with visceral leishmaniasis I.M. Medeiros,

Grepafloxacin: microbiological properties

I.J. Schalk Clinical Microbiology and Infection

Approach to diagnosis of infective endocarditis

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Herpes zoster in non-hospitalized children

Atypical respiratory pathogens

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Use of antimicrobials and resistance in bacteria isolated from blood cultures in a Danish county from 1992 to 1995 Thomas Lund S⊘rensen, Niels Frimodt-M⊘ller,

Hydatid disease Clinical Microbiology and Infection

Link between intracellular pathogens and cardiovascular diseases

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species Jacques Dubois, Claude St-Pierre Clinical.

Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente

Toxicity and efficacy of conventional amphotericin B deoxycholate versus escalating doses of amphotericin B deoxycholate—fat emulsion in HIV-infected.

Structure of grepafloxacin relative to activity and safety profile

Vector control: a cornerstone in the malaria elimination campaign

Inga Odenholt, Elisabeth Löwdin, Otto Cars

Fourth-generation cephalosporins: a review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility Javier Garau, Walter Wilson,

C-3′Quaternary Ammonium Cephems, a New Wave of Cephalosporins

Sofie Arens, Jan Verhaegen, Ludo Verbist

Multicenter study of the in vitro activity of cefepime in comparison with five other broad- spectrum antibiotics against clinical isolates of Gram-positive.

Training for the infectious diseases speciality in Norway

The antibacterial effects of ciprofloxacin and trovafloxacin against Streptococcus pneumoniae in an in vitro dynamic model Matthew O'Brien, Thuy Quach,

Cephalosporins: a pharmacological update

Epidemiology of opportunistic infections in AIDS patients

Laboratory diagnosis and biosafety issues of biological warfare agents

Sepsis and neutropenia induced by clozapine

Gastrointestinal and respiratory Mycobacterium avium colonization and development of disseminated infection in HIV-positive patients Giampietro Nardi,

Uncommon opportunistic fungi: new nosocomial threats

André Bryskier Clinical Microbiology and Infection

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

Effect of antioxidants on the immune response of Helicobacter pylori

Laboratory diagnosis of Clostridium difficile disease

W.A. Craig Clinical Microbiology and Infection

Interactions between cytomegalovirus and the p53 tumor suppressor gene in atherosclerotic vascular disease Inge O. Baas, G. Johan A. Offerhaus, Ralph.

G.R. Davies Clinical Microbiology and Infection

J. Garau Clinical Microbiology and Infection

Community-acquired pneumonia: epidemiologic and clinical consideration

Grepafloxacin: pharmacokinetics and tissue penetration

Training in infectious diseases and tropical medicine in Britain

Fibronectin concentrations in catheter sepsis

Clinical infection services—the Leiden experience

Statin use and clinical outcomes among pneumonia patients

Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin G. Drusano Clinical Microbiology and Infection

Clinical Microbiology and Infection

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Miles Denton, Kevin G Kerr, Fraser Lewis Clinical.

Clinical Microbiology and Infection

Overview of cefixime use in community-acquired infections

The atypical pneumonias: clinical diagnosis and importance

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Facilitating learning and change in physicians: Implications for a system of continuing medical education in Europe Robert D. Fox Clinical Microbiology.

Abstracts Clinical Microbiology and Infection

New oral cephalosporins in pediatric community-acquired infections

Typing of Clostridium difficile

New patterns of HIV-1 resistance during HAART

J.A. Pérez-Molina, F. Fernández Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Localized Mycobacterium avium complex infection in a patient on HAART

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Vincent Calvez, Marc Grandadam Clinical Microbiology and Infection

Presentation transcript:

Twice-weekly dapsone for primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1 infection: efficacy, safety and pharmacokinetic data M. Cruciani, E. Bertazzoni Minelli, M. Mirandola, R. Luzzati, M. Merighi, L. Lazzarini, G. Gatti, S. Vento, R. Mazzi, M. Malena, A. Benini, A. Cazzadori, G. Piemonte, D. Bassetti, E. Concia Clinical Microbiology and Infection Volume 2, Issue 1, Pages 30-35 (August 1996) DOI: 10.1111/j.1469-0691.1996.tb00197.x Copyright © 1996 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 1 Plasma concentration-time profiles at steady state following the administration of dapsone (100 mg) to three male patients. Clinical Microbiology and Infection 1996 2, 30-35DOI: (10.1111/j.1469-0691.1996.tb00197.x) Copyright © 1996 European Society of Clinical Infectious Diseases Terms and Conditions

Figure 2 Dapsone steady-state concentrations in serum in 42 HIV-infected patients after oral administration (100 mg twice weekly). Δ=mean values; •= female; ∘=male. Clinical Microbiology and Infection 1996 2, 30-35DOI: (10.1111/j.1469-0691.1996.tb00197.x) Copyright © 1996 European Society of Clinical Infectious Diseases Terms and Conditions